ASK4SAM by Silberstein & Miklos, P.C. Expands Focus on Delayed Diagnosis Medical Malpractice Cases in Manhattan and Long Island

Redo Announces $81 Million Series B to Support Commerce Technology Expansion

In this episode of Global Economic Press, Alex Brady delves into the significant developments in commerce technology as Redo, a leading company in the field, announces an impressive eighty-one million dollar Series B funding round. This investment, led by Smash Capital with participation from Pelion Venture Partners and Cervin Ventures, positions Redo at a valuation of one billion two hundred fifty million dollars. The funding will be utilized to enhance product development, artificial intelligence initiatives, and international expansion, enabling Redo to continue building technology that aids brands in managing customer relationships across various commerce touchpoints. Redo, originally founded as a post-purchase platform focused on returns and exchanges, has broadened its offerings to include order tracking, package protection, fulfillment support, customer service tools, marketing capabilities, and artificial intelligence-powered commerce experiences. With more than four thousand one hundred brands using Redo's platform, the company is committed to developing artificial intelligence-driven commerce tools to support customer engagement throughout the shopping journey. The recent acquisition of ReturnBear, a provider of international returns, further expands Redo's ability to streamline shopper experiences globally. As artificial intelligence continues to transform commerce, Redo aims to provide the infrastructure that helps brands own and strengthen direct relationships with shoppers. For more information about Redo and its innovative solutions, visit their website at Redo [https://redo.com/].

AM Rx Announces Expanded Online Access and Insurance Support for Zepbound

In this episode of Global Economic Press, Alex Brady discusses the recent announcement by AM Rx regarding the expansion of its online access and insurance support for Zepbound, a weight-management medication. AM Rx's initiative aims to streamline the process for patients seeking prescription weight-loss treatments by offering virtual medical evaluations, prescription management, and insurance coordination. The program also includes one-on-one coaching and ongoing communication with licensed healthcare providers. This expansion is designed to help patients navigate insurance coverage and authorization processes, ensuring they remain connected with their care team throughout their treatment journey. Zepbound, which contains tirzepatide, is approved by the Food and Drug Administration for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. AM Rx's program offers various support services, including insurance-benefit verification and prior-authorization submissions, although insurance companies retain control over coverage decisions. The program also provides personalized weight-management plans and secure provider messaging. AM Rx offers an introductory membership priced at thirty-nine dollars for the first month, with subsequent renewals at one hundred thirty-five dollars per month. For more information about AM Rx and its services, visit GetAMRx.com [https://getamrx.com].

Zealthy Launches Enhanced Weight-Loss Care Platform With Integrated Zepbound Access and Insurance Support

In this episode of Global Economic Press, Alex Brady explores the innovative virtual healthcare solutions offered by Zealthy, focusing on their newly launched enhanced weight-loss care platform. This platform integrates telehealth services, insurance support, and prescription management to provide a comprehensive digital care experience. Zealthy's approach aims to simplify access to obesity treatment by allowing patients to complete an online health assessment, connect with licensed healthcare providers, and receive treatment recommendations through a fully digital interface. The platform also includes access to medications like Zepbound, a once-weekly injectable medication approved by the Food and Drug Administration for weight management and other health conditions. Zealthy's weight-loss program offers a standard membership starting at $39 for the first month, with subsequent months priced at $135. The program includes access to medical providers, prescription management, insurance coordination, and weight-loss coaching. While the cost of medications like Zepbound is generally separate, Zealthy assists patients in navigating insurance coverage and prior-authorization requirements. The company provides a convenient online pathway for eligible patients to receive prescriptions and ongoing support. For more information about Zealthy and their services, visit their official website at https://getzealthy.com [https://getzealthy.com].

RoenRx Releases 2026 Weight-Loss Program Pricing and Treatment Cost Overview

In this episode of Global Economic Press, Alex Brady delves into the recent announcement by RoenRx, a telehealth platform, regarding its 2026 pricing for its weight-loss program. RoenRx has unveiled a comprehensive pricing structure that includes membership costs, insurance-supported GLP-1 treatment options, compounded medication pricing, and bundled care plans. The aim is to provide prospective patients with transparency about the costs associated with their weight-management services. The podcast explores the financial implications of these new pricing strategies and the opportunities they present for individuals seeking medically supervised weight-loss solutions. RoenRx offers a range of services, including access to GLP-1 medications, licensed providers, and optional weight-loss coaching. The standard weight-loss membership is advertised at $39 for the first month, with subsequent months priced at $135. However, this introductory price does not typically include medication. Depending on the medication, insurance coverage, and payment plan, the total monthly cost can range from approximately $160 to $449. RoenRx provides detailed information on its pricing, including options for compounded semaglutide and tirzepatide, bundled plans, and insurance coverage. For more information, visit RoenRx's website at https://roenrx.com [https://roenrx.com].

Featured Launches AI-Powered Podcast Discovery Tool Backed by Database of 814,000 Active Shows

In this episode of Global Economic Press, Alex Brady delves into the transformative world of podcasting and public relations with the introduction of a groundbreaking tool from Featured. This AI-powered podcast discovery tool is designed to revolutionize how public relations professionals, authors, and experts find active podcast opportunities. By analyzing over five million podcasts and narrowing the field to approximately 814,000 active shows, Featured addresses the challenge of identifying which podcasts are still publishing and booking guests. This innovation is set to change the landscape of earned media by allowing users to efficiently discover relevant podcasts through natural-language searches. Featured's new tool simplifies the process of finding podcasts to pitch by allowing users to describe their desired show in plain language, such as by topic, audience, format, or niche. This natural-language interface transforms podcast discovery into a single request, consistent with Featured's role as an AI co-pilot for public relations. The tool is particularly beneficial for public relations professionals managing client visibility, founders building personal brands, authors promoting books, and consultants growing their practices. By removing the bottleneck in podcast outreach, Featured empowers users to focus on pitching shows that are actively publishing. To learn more about Featured and its offerings, visit Featured's website [https://featured.com].